Expression of Bcl-2 protein and incidence of apoptosis of parietal layer epithelium cell glomerulus of kidneys in male rats (Rattus norvegicus wistar) on application of glutamin nephroprotective that are exposed to nephrotoxyc modality of cisplatin chemotherapy

Abstract

Cisplatin or (SP-4-2)-diamminedichloroplatinum (II) is one of the most potential platinum derivatives and is widely used for the treatment of various solid cancers such as testes, ovarian, head and neck, bladder, lung, and cervical cancers; melanoma; and lymphoma. The proapoptotic mechanism produced by cisplatin is quite effective in treating neoplastic cells. Cisplatin therapy is a non-target therapy. The cancer cell to which cisplatin is targeted inhibits several antiapoptotic regulators, so that cancer cells immediately start apoptosis. Increased apoptosis causes decreased Bcl-2 protein expression. This research is aimed at analyzing the effect of intravenous glutamine on the expression of Bcl-2 protein in the incidence of apoptosis in parietal layer epithelial cells of the glomerulus of male rats exposed to cisplatin. Glomerular epithelial cells are investigated as a marker of damage to the glomerulus. This study adopted an experimental design with “The Randomized Post Test Only Control Group Design” with a total sample size of 30 male rats that were randomly divided into three groups (randomized). Each group consisted of 10 male rats. Group P0 was a control without any injection, only standard diet; P1 group was injected intraperitoneally with a dose of 20 mg/kg of cisplatin on seventh day; and group P2 was injected intravenously with a dose of 100 mg/kgBW of glutamine for seven days then injected intraperitoneally with 20 mg/kg of cisplatin on seventh day. There was no significant effect but moderate correlation change with p > 0.05 administration of intravenous glutamine on the expression of Bcl-2 proteins in the parietal layer epithelial cell glomerulus the incidence of apoptosis male rats exposed to cisplatin.

References

  • Alibakhshi, T. Khodayar MJ, Khorsandi L, Rashno M, Zeidooni L. (2018) ‘Protective effects of zingerone on oxidative stress and inflammation in cisplatin-induced rat nephrotoxicity’, Biomedicine and Pharmacotherapy, 105(March), pp. 225–232. doi: 10.1016/j.biopha.2018.05.085.
  • Altınkaynak, Y, Kural B, Akcan BA, Bodur A, Özer S, Yuluğ E, et al. et al. (2018) ‘Protective effects of L-theanine against doxorubicin-induced nephrotoxicity in rats’, Biomedicine and Pharmacotherapy, 108(September), pp. 1524–1534. doi: 10.1016/j.biopha.2018.09.171.
  • Balitbangkes. ( 2019) Laporan Nasional Riskesdas 2018. Jakarta: Balitbangkes p.169
  • Bastard, J. P. Fellahi S, Regeniter A, Capeau J, Ronco P, Plaisier E. (2019) ‘Aside from acute renal failure cases, are urinary markers of glomerular and tubular function useful in clinical practice?’, Clinical Biochemistry. Elsevier, 65(June 2018), pp. 1–6. doi: 10.1016/j.clinbiochem.2019.01.006.
  • Famurewa, A. C. Aja PM, Maduagwuna EK, Ekeleme-Egedigwe CA, Ufebe OG, Azubuike-Osu SO. (2017) ‘Antioxidant and anti-inflammatory effects of virgin coconut oil supplementation abrogate acute chemotherapy oxidative nephrotoxicity induced by anticancer drug methotrexate in rats’, Biomedicine and Pharmacotherapy. Elsevier, 96(December), pp. 905–911. doi: 10.1016/j.biopha.2017.12.008.
  • Filipski, K., Mathijssen, R., Mikkelsen, T. et al. (2009). Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity. Clinical Pharmacology & Therapeutics, [online] 86(4), pp.396-402.
  • Gao, H, Zhang S, Hu T, Qu X, Zhai J, Zhang Y, et al. (2019) ‘Omeprazole protects against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and transporter-mediated cisplatin accumulation in rats and HK-2 cells’, Chemico-Biological Interactions. Elsevier, 297(June 2018), pp. 130–140. doi: 10.1016/j.cbi.2018.11.008.
  • Ghosh, S. (2019). Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry, 88, p.102925.
  • Gómez-Sierra, T, Eugenio-Pérez D, Sánchez-Chinchillas A, Pedraza-Chaverri J. (2018) ‘Role of food-derived antioxidants against cisplatin induced-nephrotoxicity’, Food and Chemical Toxicology. Pergamon, 120, pp. 230–242. doi: 10.1016/J.FCT.2018.07.018.
  • Hernandez RK, Adhia A, Wade SW, O’Connor E, Arellano J, Francis K, et al ( 2015 ). Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clin Epidemiol.;7:335–45.
  • Judd, E. and Calhoun, D. A. (2015) ‘Management of hypertension in CKD: beyond the guidelines’, Advances in chronic kidney disease, 22(2), pp. 116–122. doi: 10.1053/j.ackd.2014.12.001.
  • Karner-Hutuleac, A. (2012) ‘Health related quality of life of diabetic and chronic renal failure patients’, Procedia - Social and Behavioral Sciences. Elsevier, 33, pp. 85–89. doi: 10.1016/J.SBSPRO.2012.01.088.
  • Kim, H. J, Park DJ, Kim JH, Jeong EY, Jung MH, Kim TH, et al. (2015) ‘Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation’, Journal of Pharmacological Sciences. Elsevier Ltd, 127(1), pp. 117–126. doi: 10.1016/j.jphs.2014.11.009.
  • Portt, L, Norman G, Clapp C, Greenwood M, Greenwood MT. (2011) ‘Anti-apoptosis and cell survival: A review’, Biochimica et Biophysica Acta - Molecular Cell Research. Elsevier B.V., 1813(1), pp. 238–259. doi: 10.1016/j.bbamcr.2010.10.010.
  • Prasaja, Y., Sutandyo, N. and Andrajati, R. (2015) “Incidence of Cisplatin-Induced Nephrotoxicity and Associated Factors among Cancer Patients in Indonesia,” Asian Pacific Journal of Cancer Prevention. Asian Pacific Organization for Cancer Prevention, 16(3), pp. 1117–1122. doi: 10.7314/apjcp.2015.16.3.1117.
  • Quintanilha, Saavedra KF, Visacri MB, Moriel P, Salazar LA. (2019) ‘Role of epigenetic mechanisms in cisplatin-induced toxicity’, Critical Reviews in Oncology/Hematology. Elsevier, 137(August 2018), pp. 131–142. doi: 10.1016/j.critrevonc.2019.03.004.
  • Tsuruya, K, Ninomiya, T, & Tokumoto, M 2003, Direct Involvement of The Receptor-mediated Apoptotic Pathways in Cisplatin-induced Renal Tubular Cell Death, Kidney Int, vol 63, pp 72-82
  • Verratti, V, Brunetti L, Ferrante C, Orlando G, Recinella L, Chiavaroli A, et al. (2019) ‘Physiological and pathological levels of prostaglandin E2 in renal parenchyma and neoplastic renal tissue’, Prostaglandins & Other Lipid Mediators. Elsevier, 141, pp. 11–13. doi: 10.1016/J.PROSTAGLANDINS.2019.02.004.
  • Yang, X, Le Minh H, (Tim) Cheng K-T, Sung KH, Liu W. (2016) ‘Renal compartment segmentation in DCE-MRI images’, Medical Image Analysis. Elsevier, 32, pp. 269–280. doi: 10.1016/J.MEDIA.2016.05.006.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.